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1. Introduction 
The metabolic syndrome is a clustering of traditional cardiometabolic risk factors that include 
central obesity, dysglycemia, hypertension, hypertriglyceridemia, and reduced high-density 
lipoprotein (HDL) cholesterol. In recent years, its clinical utility, diagnostic criteria and 
underlying etiology have been the subject of continuous debate and controversy. While the 
debate continues, it remains incontrovertible that those identified with the metabolic 
syndrome are at high risk for the future development of type 2 diabetes (T2DM) and 
cardiovascular disease (CVD). In addition, an expanding body of evidence has linked the 
metabolic syndrome with several emerging non-traditional risk factors, including markers of 
hepatic fat, chronic inflammation (such as C-reactive protein (CRP)), and adipocyte 
dysregulation (such as low circulating levels of adiponectin). Interestingly, many of these 
features of the metabolic syndrome are also common to gestational diabetes mellitus (GDM). 
Indeed, GDM has also been the subject of longstanding debate throughout its history and it 
too identifies women who are at high  risk of developing T2DM and CVD in the future. 
Moreover, in recent years, GDM has been similarly linked to an array of non-traditional 
cardiometabolic risk factors, including CRP and hypoadiponectinemia. A series of studies 
have demonstrated that women with GDM are at risk of developing the metabolic syndrome 
in the years following their index pregnancy. Furthermore, emerging evidence shows that 
components of the metabolic syndrome identified in early gestation and even prior to 
pregnancy can predict the subsequent development of GDM. Taken together, these findings 
have raised the intriguing possibility that women who develop GDM may have an underlying 
latent metabolic syndrome that warrants clinical evaluation and risk factor modification.  
Though intricate and still incompletely understood, the gradual expansion of knowledge 
about inter-relationships between the metabolic syndrome, GDM and T2DM may provide 
us with opportunities to screen for and detect metabolic dysfunction at various stages of 
disease progression. In this way, GDM represents an important and early “metabolic flag” 
for an affected mother and, perhaps, her offspring. Thus, in this chapter, we explore the 
emerging relationship between GDM and the metabolic syndrome. We review the 
definitions of each condition, their limitations and controversies, and their utility and 
predictive value in identifying T2DM and CVD risk. The clinical evidence for metabolic 
syndrome as a precursor to the development of GDM and, in turn, T2DM is also discussed. 
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Emerging non-traditional risk factors for both metabolic syndrome and GDM will be 
described, alongside the evidence for metabolic syndrome as a consequence of GDM and as 
a potential predictive tool to detect risk for GDM before and during early pregnancy. 
Finally, we consider the concept that women who develop GDM may have a latent 
metabolic syndrome.  
2. Metabolic syndrome 
2.1 General definition and varying sets of diagnostic criteria 
The metabolic syndrome, also referred to as the insulin resistance syndrome, was initially 
proposed as a model for understanding the underlying biology and risk factors for CVD. In 
his Banting award lecture, Gerald Reaven first described ‘Syndrome X’ as the clustering of 
abnormalities related to insulin resistance (Reaven, 1988). The World Health Organization 
formally proposed the term ‘metabolic syndrome’ in 1998 (Alberti et al., 1998; DeFronzo & 
Ferrannini, 1991) to identify those at high risk for metabolic disorders and CVD. Though the 
syndrome was originally intended to identify individuals at risk for CVD, it has since 
expanded to capture those at high risk for T2DM, with which it is thought to have a stronger 
association (Ford et al., 2008). The definition of metabolic syndrome continues to evolve 
today, and is widely studied as a promising marker of cardiovascular risk. 
The syndrome is characterized by a clustering of central abdominal (visceral) obesity, 
glucose intolerance, insulin resistance, dyslipidemia and hypertension (Reaven, 1988). The 
presence of any one risk factor implies the existence of others, such that their concomitant 
occurrence collectively describes a positive dysmetabolic risk profile for CVD, or 
‘cardiometabolic risk’ (Despres et al., 2008).  
While several organizations and authoritative bodies have proposed diagnostic criteria for 
the metabolic syndrome, the most cited working definitions are those of the International 
Diabetes Federation (IDF), the World Health Organization (WHO), and the National 
Cholesterol Education Program – Adult Treatment Panel III (NCEP-ATP III) (Alberti et al., 
2005; WHO Expert Consultation, 2004; Alexander et al., 2003). These authorities have 
synthesized, analyzed and translated information gathered from a vast, globally 
representative body of research studies, in order to provide a set of diagnostic criteria with 
clinically relevant thresholds and measurements that can identify the metabolic syndrome 
and hence the risk of diabetes and CVD. Despite continued efforts, there are variations in 
the definitions, which have prompted international debate about the actual utility and 
strength of the metabolic syndrome as a diagnostic tool. Table 1 lists the criteria and 
diagnostic thresholds defined by the IDF, WHO, NCEP ATP-III, and, lastly, the recently 
published harmonized criteria (discussed in section 2.2). 
Although the ATP III and IDF definitions differ in their diagnostic threshold criteria for 
metabolic syndrome, both include the same 5 components: increased adiposity, 
hypertriglyceridemia, low levels of high density lipoprotein cholesterol (HDL-C), 
hypertension and dysglycemia. The WHO definition also includes a urine albumin to 
creatinine ratio. Meeting the dichotomous cut-off points for an abnormality in 3 or more of 
the 5 components fulfills the requirements for diagnosis according to the ATP III definition 
(Hunt et al., 2004). Though all definitions include an obesity criterion, the IDF definition 
provides ethnicity-specific values for diagnosing abdominal obesity (Reaven, 2009). 
Moreover, for diagnosing metabolic syndrome, the IDF definition requires the presence of 
increased waist circumference (WC) as a necessary prerequisite along with any 2 of the 
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other criteria. Elevated triglycerides and/or low HDL-C must fall within the prescribed 
threshold or can be applied if a person is being treated specifically for the lipid abnormality. 
In addition, the defining criteria consider those with T2DM, an elevated WC and at least 1 
other risk factor as having metabolic syndrome. The WHO requires the presence of diabetes, 
impaired fasting glucose (IFG), impaired glucose tolerance (IGT) or insulin resistance and at 
least 2 other criteria. Among the 3 definitions, the IDF and ATP III are more commonly cited 
within the recent literature. The prevalence of metabolic syndrome in U.S. adults is 
estimated to be approximately 22% to 34% using the ATP III definition and 39% when the 
IDF criteria are applied (Ford, 2005).  
 
 NCEP-ATP III IDF WHO 
Harmonized 
IDF/AHA 
Central obesity 
WC >102 cm- (M) 
WC >88 cm- (F) 
WC >94 cm- White (M)
WC >80 cm- White (F)
WC >90cm- Asian (M)
WC >80cm- Asian (F) 
Waist-to-hip ratio: 
>0.90- (M) 
>0.85- (F) 
 
Same as IDF cut 
points for non-
Europeans & either 
IDF or AHA criteria 
for Europeans 
Elevated 
triglycerides 
>1.7 mmol/L >1.7 mmol/L  >1.7 mmol/L >1.7 mmol/L 
Reduced  
 HDL-C 
<1.0 mmol/L- (M)
<1.3 mmol/L- (F)  
<1.03 mmol/L- (M) 
<1.29 mmol/L- (F) 
<0.9 mmol/L- (M) 
<1.0 mmol/L- (F) 
<1.0 mmol/L- (M) 
<1.3 mmol/L- (F) 
Elevated blood 
pressure 
>130/85 mm Hg >130/85 mm Hg >140/90 mm Hg 
Systolic >130 and/or 
diastolic >85 mmHg 
Fasting 
hyperglycemia 
>6.1 mmol/L  
>5.6 mmol/L or  
diabetes or IGT  
Diabetes, IFG, IGT >5.6 mmol/L 
Urine albumin: 
creatinine ratio 
- - > 3.4 mg/mmol - 
Table 1. Various diagnostic criteria for the metabolic syndrome 
2.2 Controversy regarding the metabolic syndrome 
The debate surrounding the metabolic syndrome stems from disagreement about its definition 
and diagnostic criteria, alongside questions related to its pathogenesis, origins, and 
applicability across populations. However, despite this ongoing debate, central obesity and 
insulin resistance have been widely postulated (Lann & LeRoith, 2007) as comprising the 
fundamental basis of the metabolic syndrome. Categorically, the syndrome is influenced by 
the complex genetic, hormonal and nutritional origins of its individual component risk factors.  
Discrepancies among the commonly used NCEP-ATP III, IDF and WHO definitions of the 
metabolic syndrome, have contributed substantially to this debate. For example, ATP III and 
WHO differ in their criteria for blood pressure, and neither definition provides specific 
guidance on how to implement these diagnostic thresholds (i.e., whether to use abnormal 
systolic vs. diastolic or both; whether to obtain measures in a particular body position; or 
whether to calculate an averaged measure). Recently, the American Heart 
Association/National Heart, Lung and Blood Institute (AHA/NHLBI) and IDF attempted to 
resolve such discrepancies with new harmonized criteria. These criteria, shown in Table 1, 
include (i) clarification of the blood pressure measurement to specify elevated levels of 
systolic and/or diastolic pressure and (ii) elimination of abdominal obesity as a mandatory 
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prerequisite, such that the presence of any 3 of the 5 criteria is sufficient for diagnosis of 
metabolic syndrome (Alberti et al., 2010). The ATP III and IDF definitions differ in their 
criteria for increased fasting glucose and central obesity (using WC) (Alberti et al., 2006; 
NCEP 2001) and while obesity is measured by WC according to the ATP III and IDF 
definitions, waist-to-hip ratio is used in the WHO definition. Furthermore, urine albumin-
creatinine ratio is a criterion in the WHO definition, but is not found in the ATP III and IDF 
definitions, while several risk factors associated with insulin resistance are not considered in 
any of the definitions, including physical inactivity, family history, sex and age  (Kahn et al., 
2005).  
Further complicating the controversy is the practical observation that, despite its centrality 
to the metabolic syndrome, contrasting evidence suggests that many overweight or obese 
individuals may, by any guideline, have normal metabolic profiles (Wildman et al., 2008), 
and are not prone to future development of metabolic syndrome. Similarly, among those 
who display metabolic syndrome, not all are obese (Bruce & Hanson, 2010). Some lean 
individuals are insulin resistant and exhibit increased cardiometabolic risk. In a study of 
otherwise healthy obese individuals and insulin resistant lean individuals with a family 
history of T2DM, obesity was associated with higher insulin resistance and diastolic blood 
pressure, but conveyed no difference in other metabolic markers. In addition, within each 
BMI category, insulin resistance independently predicted metabolic syndrome, while WC 
did not. Only when age was combined with WC (but not BMI) did obesity independently 
predict metabolic syndrome, and, even so, WC was less predictive of insulin resistance at 
higher WC values (Utzschneider et al., 2010). The authors concluded that insulin sensitivity 
is a stronger predictor of metabolic syndrome than obesity, and is better than WC at 
identifying obese individuals with an otherwise healthy metabolic profile. They also 
recommended employing metabolic testing among lean individuals with a first-degree 
relative with T2DM (Utzschneider et al., 2010). Nevertheless, even when weight is 
considered, cut-points used to define obesity are not universally agreed upon and may vary 
by ethnicity (Despres et al., 2008).  
The use of different definitions of the metabolic syndrome has clouded our ability to 
compare findings across research studies. In addition, there is the question of whether the 
diagnostic criteria are too restrictive, missing those at highest risk, or, conversely, are too 
broad, resulting in an overestimation of the prevalence of  metabolic syndrome. Considering 
its inherently chronic and progressive nature, it is reasonable to infer that indicators of 
dysmetabolism, especially in younger adults, underestimate its consequences for predicting 
T2DM and CVD. Indeed, manifestation may even occur at different time-points in the 
disease trajectory, such that risk factor assessment necessitates systematic evaluation across 
a spectrum of sub-diagnostic and diagnostic ranges standardized for age.  
Another criticism of the metabolic syndrome is whether its value extends beyond that of its 
individual components. The criticism highlights both the redundancy of the classification as 
a ‘syndrome’ and the inadvertent undermining of the importance of the individual 
components. The diagnosis of metabolic syndrome, by any definition, has been studied in 
relation to the predictive value of the individual criteria. The Framingham study (Wilson et 
al., 2005) demonstrated no substantial increase in risk associated with clusters of 3 of the 5 
metabolic syndrome criteria compared with clusters of only 2 traits. In contrast, data from 
the Third National Health and Nutrition Examination Survey (Ninomiya et al., 2004) 
indicated that each of the 5 components of metabolic syndrome was an independent 
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predictor of CVD. These studies illustrate the controversy over whether a diagnosis of 
metabolic syndrome provides more useful information about CVD risk than any of its 
individual components (Reaven, 2009). Furthermore, by the current definitions, it is unclear 
whether any one risk factor is more predictive than the other, in the form of a weighted 
hierarchy. 
To address these criticisms, the American Diabetes Association (ADA) and European 
Association for the Study of Diabetes (EASD) issued a joint statement about the clinical 
utility of the metabolic syndrome; they recommended that clinicians evaluate and treat 
discrete risk factors, without diagnosing the metabolic syndrome, per se (Kahn et al., 2005). 
Specifically, rather than solely relying on diagnosis of metabolic syndrome, identification of 
one or more of its component features should prompt investigation for the presence of the 
other features. For the latter, one may also consider specific emerging risk factors not 
included in the existing definition, as outlined below. 
2.3 Metabolic syndrome and the identification of future risk of T2DM and CVD 
The IDF recommends screening for metabolic syndrome features in those with T2DM 
(Alberti et al., 2006, Alberti et al., 2005). While current recommendations are subject to 
criticism and controversy, they nevertheless provide a practical basis upon which to adopt 
management strategies. Individuals with metabolic syndrome have a 5-fold higher risk of 
developing T2DM (Alberti et al., 2010). Similarly, in a study from the UK that examined the 
prognostic impact of metabolic syndrome in T2DM, the investigators modified the ATP III 
definition to include BMI instead of WC, and found that the metabolic syndrome further 
predicted CVD incidence five years after the diagnosis of T2DM (Guzder et al., 2006).  
Showing that dysglycemia predicts metabolic syndrome necessarily identifies a predictive 
potential for T2DM as well. This is so given that metabolic syndrome -- and especially 
glucose intolerance -- is central to the development of T2DM. In the GENFIEV study, 
metabolic syndrome prevalence was 42% in those with IFG, 34% in IGT, and 74% in IFG + 
IGT (Bianchi et al., 2010). In addition, the prevalence of insulin resistance was higher in 
those with metabolic syndrome than in its absence. Hypertriglyceridemia (odds ratio [OR] 
3.38; 95% confidence interval [CI] 2.29-4.99), abdominal obesity (3.26; 95% CI 2.18-4.89), 
hyperglycemia (3.02; 95% CI 1.80-5.07) and hypertension (1.69; 95% CI 1.12-2.55) were all 
associated with insulin resistance. These findings suggest that the prevalence of the 
metabolic syndrome is high in individuals with dysglycemia, and is generally associated 
with insulin resistance (Bianchi et al., 2010). Moreover, dysglycemia and insulin resistance 
are highly predictive of T2DM. Similarly, long-term glycemic excursions will identify those 
at high risk for metabolic syndrome and T2DM. In their exploratory study, Giuffrida et al. 
(2010) investigated the relation between glycated hemoglobin (GHb), an indicator of long-
term glycemic control, and metabolic syndrome with T2DM. Each 1% increase in GHb was 
associated with metabolic syndrome (OR 1.31, 95% CI 1.18–1.45), demonstrating a strong 
relation between chronic hyperglycemia and metabolic syndrome (Giuffrida et al., 2010).  
Aboriginal Canadians have a 5-fold higher risk of T2DM compared to non-Aboriginals. 
Among the former, the metabolic syndrome can be readily identified using available clinical 
measures, and thus, may be a useful clinical tool (Reaven, 2009; Ley et al., 2009). In a 
prospective study, Ley and colleagues (2009) found that the 10-year cumulative incidence of 
T2DM in the Aboriginal Canadian population was 17.5%, with an age-dependent gradient 
ranging from 10.5% among those aged 10–19 years, to 43.3% among those aged 40–49 years. 
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The authors reported that, at baseline, metabolic syndrome had a low positive predictive 
value for future diabetes; however, the syndrome predicted incident diabetes to the same 
degree as IGT, while its high negative predictive value identified disease-free individuals at 
follow-up (Ley et al., 2009).  
In addition to identifying those at risk of T2DM, metabolic syndrome also independently 
predicts risk of CVD. In the joint statement from the ADA and the EASD (2005), the authors 
emphasized the practical use of the metabolic syndrome, focusing on its predictive value for 
CVD (Kahn et al., 2005). A meta-analysis of a series of European trials reported that 
metabolic syndrome raises the hazard ratio for CVD in women from 0.6 to 2.8 (Hu et al., 
2004). Moreover, patients with metabolic syndrome are at twice the risk of developing CVD 
over a 5-10 year period than those without the syndrome (Alberti et al., 2010). Several 
population studies have described an increased cardiovascular risk in the presence of 
metabolic syndrome (Alexander et al., 2003; Ford, 2004, 2005; Hunt et al., 2004; Isomaa et al., 
2001; McNeill et al., 2005). Alexander and colleagues (2003) used the ATP III criteria to 
assess the prevalence of coronary heart disease (CHD) among patients with the metabolic 
syndrome. They reported that those without metabolic syndrome, regardless of diabetes 
status, had a low CHD prevalence (less than 10%), while those with diabetes but not the 
metabolic syndrome exhibited no increased risk of CHD (Alexander et al., 2003). Otherwise, 
metabolic syndrome was a significant predictor of CHD (OR 2.07, 95% CI 1.66-2.59) and 
conferred a risk beyond that of diabetes alone (Alexander et al., 2003).  
In the San Antonio Heart Study, metabolic syndrome at baseline was a significant predictor 
of cardiovascular mortality over a mean follow-up of 13 years  (Hunt et al., 2004). Similarly, 
using the WHO definition, Isomaa and colleagues (2001) found that the risk for CHD and 
stroke was increased 3-fold in those with the metabolic syndrome (P < 0.001), as was 
cardiovascular mortality (P < 0.001) (Isomaa et al., 2001). In a study of individuals without 
diabetes or CVD at baseline, the ATP III– defined metabolic syndrome had an adjusted 
hazard ratio of CHD of 1.46 (95% CI, 1.23–1.74) for men and 2.05 (95% CI, 1.59–2.64) for 
women (McNeill et al., 2005).  
Ford and colleagues (2004) showed a linear association between ATP III-based metabolic 
syndrome and CVD-related mortality as well as all-cause mortality (Ford et al., 2004). A 
meta-analysis of worldwide data from studies published between 1998 and 2005, showed 
pooled relative risks (RR) of 1.27 (95% CI, 0.90–1.78) for all-cause mortality, 1.65 (95% CI, 
1.38–1.99) for CVD and 2.99 (95% CI, 1.96–4.57) for T2DM using ATP III-defined metabolic 
syndrome; in the fewer studies that used the most exact WHO definition, the pooled RRs 
were 1.37 (95% CI, 1.09–1.74) for all-cause mortality and 1.93 (95% CI, 1.39–2.67) for CVD 
(Ford, 2005). Thus, there is considerable evidence for the predictive value of the metabolic 
syndrome for identifying risk of T2DM and CVD. 
2.4 Metabolic syndrome and emerging non-traditional risk factors  
As the components of metabolic syndrome continue to be better understood, the syndrome 
appears to be a promising diagnostic and screening tool. Recent studies have identified 
chronic low-grade inflammation as a systemic consequence of obesity that is related to both 
metabolic and vascular disease. For example, the inflammatory nature of atherosclerosis 
prompted the study of inflammatory proteins, such as high-sensitivity C-reactive protein 
(CRP), as potential predictors of CVD. Indeed, epidemiological studies have shown the 
independent relation between CRP and CHD (Ridker, 1997, 1998).  
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Nakano et al, (2010) investigated the clinical significance of LDL and CRP in coronary artery 
disease (CAD) risk (Nakano et al., 2010). Among those without the metabolic syndrome, 
high CRP was not associated with a higher risk of CAD; however, those with both high CRP 
and metabolic syndrome had a doubling in their risk of CAD (Ridker et al., 2003; Sattar et 
al., 2003). Despite uncertainty regarding the utility of adding CRP to the metabolic 
syndrome definition, investigation of its potential as a predictive tool and meaningful 
addition to metabolic syndrome is advocated (Ridker et al., 2004).  
Previous studies have also examined the use of adipose tissue biomarkers, including 
adiponectin, in predicting CVD risk. Adiponectin is an adipocyte-derived polypeptide -- an 
adipokine -- that is inversely associated with obesity, insulin resistance and T2DM. As a 
protective adipokine, it inhibits gluconeogenesis and suppresses lipogenesis. Low levels of 
adiponectin result in reduced fatty acid oxidation and increased fat accumulation in the 
liver. Adipose tissue plays a central role to metabolic syndrome, and low adiponectin levels 
are associated with metabolic syndrome. In addition, the strong association between 
hypoadiponectinemia and CVD risk implicates adiponectin in the disease trajectory. 
Compared with lean controls, patients with metabolic syndrome and T2DM have lower 
circulating levels of total and  high molecular weight (HMW) adiponectin, and higher levels 
of leptin and interleukin-6 (IL-6). Decreased total and HMW adiponectin, and increased 
levels of leptin and IL-6, are characteristic of patients with metabolic syndrome and T2DM 
(Lee et al., 2009). There may also be a link between low adiponectin and fatty liver disease 
(Matsubara et al., 2004).  
Hepatic dysregulation is characterized by insulin resistance -related steatosis and oxidative 
stress (Kim & Younossi, 2008). Non-alcoholic fatty liver disease (NAFLD) -- ranging from 
simple steatosis (fatty infiltration) to inflammatory steatohepatitis (NASH), to long-term 
injury (fibrosis) -- is a strong indicator of insulin resistance in non-pregnant adults (Youssef 
& McCullough, 2002). The process of NAFLD development is in itself an extension of insulin 
resistance that reduces free fatty esterification and triglyceride storage in adipose tissue, 
subsequently resulting in the deposition of free fatty acids in non-adipose tissues, especially 
the liver (Utzschneider & Kahn, 2006). Hence, NAFLD is considered to be the principal liver 
manifestation of the metabolic syndrome (Kim & Younossi, 2008), as it requires the presence 
of insulin resistance and is closely associated with T2DM (Targher et al., 2005). In a recent 
study of adults with newly diagnosed T2DM, there was significant interplay between T2DM 
and liver injury, likely explained by NAFLD (Porepa et al., 2010). NAFLD may also be 
detected with the novel serum marker, Fetuin-A, an endogenous inhibitor of insulin 
receptor tyrosine-kinase, and a recognized “hepatokine”. Elevated plasma Fetuin-A levels 
positively predict the incidence of T2DM independent of other established risk factors (Ix et 
al., 2008; Stefan et al., 2008). In a study of 330 adults at risk for T2DM, liver fat was the 
strongest predictor of prediabetes  (Kantartzis et al., 2010) (Kantartzis et al., 2010). Among 
studied biochemical measures, serum Fetuin-A was a more significant predictor of fasting 
hyperglycemia than serum adiponectin (Kantartzis et al., 2010). In addition, individual liver 
enzymes, such as alanine aminotransferase, have varying positive associations with the 
components of the metabolic syndrome (Zhang et al., 2010).  
While hyperuricemia is prevalent among those with metabolic syndrome, its clinical utility 
remains controversial. Nonetheless, it appears to be a predictor of metabolic syndrome. One 
hypothesis is that enhanced insulin resistance due to fatty acid synthesis in the liver may be 
linked to additional purine synthesis, thereby accelerating production of uric acid. Since 
insulin resistance is considered an underlying mechanism connecting visceral obesity and 
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metabolic syndrome (Matsuura et al., 1998), it follows that insulin resistance is related to 
elevated serum uric acid levels in those with metabolic syndrome (Borges et al., 2010). While 
a sex-dependent association between hyperuricemia and metabolic syndrome is apparent, 
there is no current evidence for its association with sex hormones. Sex hormone binding 
globulin (SHBG) is a liver-derived glycoprotein regulated by insulin, which inhibits its 
production in hepatocytes. Low serum SHBG levels are associated with increased insulin 
resistance and hyperinsulinemia. In a recent review Brand et al. (2011) examined 52 
observational studies and found that, for both sexes, metabolic syndrome was associated 
with low levels of SHBG (Brand et al., 2011).  
 
 
Fig. 1. Traditional & non-traditional (bolded) cardiometabolic risk factors associated with 
metabolic syndrome. 
3. Gestational Diabetes Mellitus (GDM)  
3.1 General definition and varying sets of diagnostic criteria  
GDM, defined as glucose intolerance of varying severity with first onset in late pregnancy, 
bears many of the same risk factors as T2DM, including: older maternal age, a family history 
of T2DM, non-White ethnicity, obesity, sedentary lifestyle, and previous GDM (Dornhorst et 
al., 1992; Hedderson & Ferrera, 2008; Hillier et al., 2008; Ray et al., 2001). GDM has both 
short and long-term risks for a mother and her child. Acute maternal effects include 
pregnancy-induced hypertension and increased risk of Caesarian-section, while long-term 
www.intechopen.com
 
Gestational Diabetes and the Metabolic Syndrome 
 
149 
consequences include increased risks of T2DM and CVD. Neonatal complications include  
fetal macrosomia and the associated risk of shoulder dystocia (Athukorala et al., 2007) which 
in turn can lead to neonatal musculoskeletal and brachial plexus injury (Christoffersson & 
Rydhstroem, 2002), while long-term sequelae are childhood obesity (Metzger, 2007), 
metabolic syndrome, and higher risk of T2DM and hypertension (Athukorala et al., 2007; 
Boney et al., 2005; Joffe et al., 1998; Leon, 1998; Metzger, 2007; Reece et al., 2009).  
Though practices vary, many countries recommend that all pregnant women be screened at 
24 to 28 weeks’ gestation with a 1- hour 50-g glucose challenge test (GCT), followed by a 
confirmatory 2-hour 75-g, or 3-hour 100-g oral glucose tolerance test (OGTT). While a 
strategy of selectively screening only women at high risk of GDM may improve the true 
positive detection rates, some women without classical risk factors for GDM will be missed, 
accordingly. Table 2 outlines some commonly used diagnostic criteria for GDM. 
 
 
NDDG 
(National 
Diabetes Data 
Group) 
ADA 2003 WHO 1999 
 
IADPSG 2010 
(Harmonized) 
 
Diagnostic 
OGTT 
3-h, 100-g 3-h, 100-g 2-h, 75-g 2-h, 75-g 
OGTT-Fasting 5.8 mmol/L 5.3 mmol/L 7.0 mmol/L 5.1 mmol/L 
OGTT-1 h 10.5 mmol/L 10.0 mmol/L - 10.0 mmol/L 
OGTT-2 h 9.2 mmol/L 8.6 mmol/L 7.8 mmol/L 8.5 mmol/L 
OGTT-3 h 8.0 mmol/L 7.8 mmol/L  - - 
Abnormal 
values needed 
for diagnosis 
>2 >2 >1 >1 
Table 2. Diagnostic criteria for GDM according to commonly used definitions. 
Despite variations in diagnostic criteria, the utility of these definitions for predicting clinical 
outcomes has been demonstrated. As an example, while the ADA and WHO diagnostic 
criteria for GDM differ slightly (International Association of Diabetes and Pregnancy Study 
Group [IADPSG], 2010), the antepartum 2-hour 75g OGTT predicts adverse pregnancy 
outcomes based on both criteria: the ADA criteria resulted in an increased risk of  
macrosomia (RR 1.29, 95% CI 0.73-2.18), preeclampsia (RR 2.28, 95% CI 1.22-4.16) and 
perinatal death (RR 3.10, 95% CI 1.42-6.47) (Schmidt et al., 2001) and similar results were 
observed using the WHO criteria. Some speculate that the restrictive diagnostic criteria for 
GDM may overlook the risks faced by women with lesser degrees of dysglycemia (Ferrara et 
al., 2007; Vambergue et al., 2000). Others assert that lack of international uniformity and 
agreement of diagnostic thresholds for GDM limits their utility within clinical settings 
(Metzger & Coustan, 1998). For example, the UK guidelines recommend that only high-risk 
groups be screened (IADPSG, 2010). In Canada, screening for GDM is routinely done, but 
not in a universal manner (Wen et al., 2000). Furthermore, current guidelines do not account 
for the variable risk attributed to ethnicity, in which there are considerable differences in the 
prevalence of GDM. In a study of ethnicity and postpartum metabolism in women with 
prior GDM, South Asian Indian women had higher serum triglycerides and lower HDL-C 
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levels, while African-Caribbean women had a higher WC, blood pressure, and insulin levels 
(Savitz et al., 2008).  
3.2 Controversy regarding GDM 
Like the metabolic syndrome, GDM has also been the subject of controversy, especially 
surrounding the timing of screening, the choice of diagnostic test, and the defining 
thresholds on these tests for its identification. Existing guidelines used to identify GDM, and 
hence the high risk of T2DM following pregnancy, were initially adapted from criteria that 
were applied to the non-pregnant population; they were not designed to identify those at 
risk for adverse perinatal outcomes (IADPSG, 2010). Extensive research has led to 
modifications of the definition (Cutchie et al., 2006) following the original publication of the 
criteria (O’Sullivan & Mahan, 1964). Of note, these original criteria were based on the 
identification of those women at risk of developing diabetes in the years after the index 
pregnancy (O’Sullivan & Mahan, 1964). 
The clinical justification for screening for GDM currently focuses on the prevention of fetal 
macrosomia and associated obstetrical complications (Retnakaran et al., 2009c). Notably, this 
focus has resulted in a single set of diagnostic criteria used to identify women at risk for two 
different adverse outcomes (Retnakaran et al., 2009c), which effectively leads to the 
assumption that a diagnosis of GDM optimally identifies the risks of both macrosomia and 
postpartum prediabetes/diabetes. In a study designed to test this assumption, subjects 
representing the full spectrum of antepartum glucose tolerance  underwent a 3-hour OGTT, 
and the results showed that only fasting glucose emerged as a significant predictor for 
delivery of a large-for-gestational-age (LGA) infant, with an OR of 2.0 (95% CI 1.20-3.34) per 
1 mmol/L incremental increase (Retnakaran et al., 2009c). However, all three post-load 
measures were significant predictors of postpartum prediabetes/diabetes (1-h glucose: OR 
1.37, 95% CI 1.17-1.61; 2-h glucose: OR 1.55, 95% CI 1.32-1.83; 3-h glucose: OR 1.30, 95% CI 
1.10-1.53). Thus, fasting glucose values may better predict LGA risk, but post-load values 
better predict postpartum glucose intolerance (Retnakaran et al., 2009c). Clearly, an 
additional challenge to the GDM diagnostic definition includes how the results are applied. 
The prevailing consensus within the existing framework for diagnosing GDM is that 
hyperglycemia, including levels below those for overt diabetes, is associated with the 
adverse pregnancy outcomes common to GDM. In addition, most agree that screening for 
GDM at 24-28 weeks’ gestation identifies individuals in whom effective management can 
reduce glycemic excursions and minimize adverse perinatal outcomes. It remains to be 
determined, however, whether these current strategies can effectively reduce long-term 
risks of metabolic syndrome, T2DM and CVD in affected women (Nolan, 2011). Indeed, 
women who do not meet the prescribed thresholds for GDM may incur glucose-mediated 
fetal macrosomia (Mello et al., 1997; Rudge et al., 2000; Scholl et al., 2001; Sermer, et al., 
1995), and may be at  risk for T2DM and CVD (Retnakaran et al., 2008a, 2008b, 2009a, 2009b, 
2009c, 2009d, 2009e, 2010c; Shah et al., 2008). 
The Hyperglycemia and Adverse Pregnancy Outcome (HAPO) study was undertaken to 
examine the risks associated with glucose values below traditional thresholds used to 
diagnose GDM. The study findings were translated by the IADPSG, in order to harmonize 
the existing diagnostic criteria (Table 2). The practical implications of these revised criteria 
includes the universal adoption of a 2-hour, 75-g OGTT. In doing so, these 
recommendations may identify an increased number of women at lower risk for 
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complications. How the IADPSG recommendations will impact the risk of long-term 
development of metabolic disease remains unknown at this time (IADPSG, 2010). 
3.3 GDM and the Identification of future risk of T2DM and CVD 
It is estimated that 20 to 60% of women with a history of GDM will eventually develop 
T2DM. Indeed, the relation between GDM and T2DM is well described, and the two 
conditions share a similar pathophysiology, characterized by insulin resistance of peripheral 
tissues and insufficient secretion of insulin by the pancreatic beta cells to compensate for this 
resistance (Buchanan, 2001; Buchanan & Xiang, 2005; Retnakaran et al., 2010a). Pregnancy 
itself has been described as a “stress test” for T2DM and CVD (Reece et al., 2009). It 
necessarily involves a state of severe acquired insulin resistance that is comparable to that of 
a non-pregnant person with T2DM (Bergman, 1989). Furthermore, adult offspring with 
prediabetes, born to women with previous GDM, display an 8-times higher risk of T2DM 
(Clausen et al., 2008), demonstrating the cyclical nature of diabetes (Damm, 2009) and the 
compounding effects of dysmetabolism in pregnancy. 
Since O’Sullivan’s early research illustrating high rates of IGT in the years following GDM 
(O’Sullivan, 1991), many studies have investigated the phenomena of elevated risk of T2DM 
attributed to previous GDM. In their systematic review and meta-analysis to quantify the risk 
of T2DM following GDM, Bellamy and colleagues (2009) found that women with GDM had an 
increased risk of developing T2DM compared to those women who had normoglycemic 
pregnancies (RR 7.43, 95% CI 4.79-11.51 (Bellamy et al., 2009). Epidemiological evidence shows 
that, for all populations and ethnic groups, GDM increases the risk of T2DM (Ben-Haroush et 
al., 2004). While the shared risk factors between GDM and T2DM imply a common etiology, 
the salient message is that women with a history of GDM represent a highly vulnerable group  
for the development of T2DM. This is readily evident in the 2% prevalence of T2DM following 
GDM as early as 6 weeks postpartum, with reported rates of 50-60% at 5-10 years postpartum, 
and 70% by 28 years postpartum (Kim et al, 2002; Lauenborg et al., 2004). Furthermore, at the 
population level, the health significance of GDM is apparent in the number of individuals with 
diabetes preceded by GDM. In their meta-analysis of follow-up studies of women with 
previous GDM, Cheung and Byth (2003) calculated the population-attributable risk percent 
(PAR%) for the proportion of cases of T2DM associated with prior GDM. The PAR% ranged 
from 10-31% (Cheung & Byth, 2003). These data suggest that up to one third of parous women 
with T2DM have a history of GDM. 
In addition to identifying women at risk for T2DM, GDM also has implications for future 
risk of CVD. Indeed, women with a history of GDM are at risk for sub-clinical 
atherosclerosis (Tarim et al., 2006). Studies also show an increased prevalence of 
cardiovascular risk factors in women with previous GDM (Carr et al., 2006; Lauenborg et al., 
2005; Verma et al., 2002). Shah and colleagues (2008) used large population-based 
administrative databases to examine the CVD risk in women with a history of  GDM. They 
found that, by 11.5 years after delivery, the hazard ratio for CVD in women with GDM was 
1.71 (95% CI 1.08-2.69)(Shah et al., 2008). Moreover, even mild glucose intolerance in 
pregnancy is associated with an increased risk of CVD. Compared with normoglycemic 
women who did not receive an OGTT, those who had an abnormal GCT followed by an 
OGTT that was not diagnostic of GDM still had an increased risk of CVD within 12 years of 
the index pregnancy (Retnakaran & Shah, 2009b).  
GDM likely increases the risk for developing cardiometabolic dysfunction after an affected 
pregnancy. In a longitudinal study comprising 12-18 years of follow-up, 45% of women with 
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previous GDM went on to develop hypertension compared to only 4% in the control group 
(Mestman, 1972). Another study demonstrated significantly higher rates of dyslipidemia, 
hypertension and mortality 26 years after GDM (O’Sullivan, 1991). Further exacerbating the 
burden of disease is family history of T2DM, which adds to the elevated risk associated with  
GDM. Carr and colleagues (2006) quantified the increased risk of CVD in women with GDM 
and a family history of T2DM, compared to women without a history of GDM (OR 1.85, 95% 
CI: 1.21-2.82) (Carr et al., 2006). It is generally recommended that women with GDM 
undergo a postpartum OGTT to detect ongoing dysglycemia. If lower thresholds for GDM 
are adopted, then more women are likely to be screened for T2DM postpartum. One hopes 
that this will offer a preventive opportunity that would otherwise be missed in these 
women.  
3.4 GDM and emerging non-traditional risk factors 
CVD is described as an inflammatory disease, with analogous findings in diabetes and 
obesity (Stern, 1995). Studies have also demonstrated the presence of inflammation in GDM, 
with high concentrations of serum CRP associated with GDM, but which are attenuated by 
further adjustment for BMI (Winzer et al., 2004; Wolf et al., 2003). In a cross-sectional study 
examining the role of maternal obesity in the association between CRP and GDM, pre-
pregnancy BMI emerged as the most important determinant of serum CRP concentration, 
independent of GDM (Retnakaran et al., 2003).  It thus emerges that obesity may mediate a 
systemic inflammatory response that underlies the relation between CRP and GDM. 
Similar to its potential as a metabolic syndrome risk factor, adiponectin is also a promising 
marker of GDM. Compared to unaffected women, those with GDM have lower levels in 
pregnancy of both total and HMW adiponectin (Retnakaran et al., 2004; Retnakaran et al., 
2007). These lower levels of total and HMW adiponectin are associated with both insulin 
resistance and pancreatic beta-cell dysfunction (Retnakaran et al., 2005; Retnakaran et al., 
2007). Furthermore, hypoadiponectinemia in pregnancy independently predicts postpartum 
metabolic dysfunction, including fasting glycemia, insulin resistance and beta-cell 
dysfunction (Retnakaran et al., 2010d). Thus, hypoadiponectinemia may play a role in the 
development of T2DM in women with a history of GDM.  
Another novel marker potentially associated with GDM is the presence of a fatty liver. In 
non-pregnant women with previous GDM who underwent MRI of the liver, those with high 
liver fat had elevated fasting serum triglyceride and insulin concentrations and lower 
whole-body insulin sensitivity than those with low liver fat on MRI (Tiikkainen et al., 2002). 
Given that NAFLD is common in T2DM, Forbes and colleagues (2011) investigated the 
prevalence and risk for NAFLD among European women with previous GDM. The 
prevalence of NAFLD was much higher in women with previous GDM (38%, 95% CI 28-47) 
than in those without GDM (17%, 95% CI 10-24)(Forbes et al., 2011). 
Limited evidence exists for the association between uric acid and GDM, although its 
predictive value in T2DM makes it a promising candidate for studies of GDM. High uric 
acid levels have been detected in women with GDM (Seghieri et al., 2003), and are 
considered a marker of preeclampsia (Barden et al., 2004).  
SHBG (Smirnakis et al., 2007) is another biochemical marker of much interest. Bartha et al. 
(2000) compared serum SHBG levels between women with and without GDM, and found 
that SHBG levels were lower in the GDM group (Bartha et al., 2000). Similarly, SHBG, in 
addition to adiponectin, was shown to be lower in women with GDM than unaffected 
controls (Nanda et al., 2011). Even when measured in early pregnancy, first-trimester SHBG 
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levels were lower among women who went on to  develop GDM compared to their peers 
(187 nmol/L vs 233 nmol/L) (Thadhani et al., 2003).  
In addition to traditional measures for GDM, these emerging risk factors are the same as 
those described for metabolic syndrome arising outside of pregnancy (Figure 2). 
Accordingly, they raise the question of whether the metabolic syndrome relates to GDM. 
 
 
Fig. 2. Traditional and non-traditional (bolded boxes) cardiometabolic risk factors associated 
with GDM. 
4. Risk of metabolic syndrome and its sequelae following GDM 
4.1 Development of metabolic syndrome after GDM 
Evidence that the metabolic syndrome both precedes and follows GDM suggests an 
increased lifetime risk of T2DM in women with prior GDM. In addition to chronic beta-cell 
dysfunction, women with GDM have chronic insulin resistance that is apparent after 
delivery. Indeed, in the decade after pregnancy, many women with previous GDM exhibit 
features of the metabolic syndrome. Considering the shared risk factors of metabolic 
syndrome and T2DM, and the similarities between GDM and T2DM, it is not surprising that 
GDM is likewise associated with metabolic syndrome. Akinci and colleagues (2010) 
collected antepartum characteristics of women who developed metabolic syndrome in their 
later years. Using the ATP III and IDF definitions for metabolic syndrome, pre-pregnancy 
obesity, weight gain, and OGTT fasting glucose levels each predicted the development of 
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metabolic syndrome. Moreover, even a fasting glucose concentration above 5.5 mmol/L at 
the antepartum OGTT was an independent predictor  of metabolic syndrome (Akinci et al., 
2010).  Indeed,  many studies have demonstrated an increased prevalence of features of the 
metabolic syndrome following GDM. 
Egeland and Meltzer (2010) investigated the effects of GDM on future risk of metabolic and 
cardiovascular abnormalities. The prevalence of glucose intolerance at 15 years follow-up 
was 44.4% among women with prior GDM, vs. only 13.1% in those without GDM. WC at 15-
year follow-up was the strongest predictor of this difference (Egeland & Meltzer, 2010). 
Similarly, in a U.S. study, the prevalence of the metabolic syndrome was 27.2% 11 years 
after pregnancy in women with previous GDM, compared to only 8.2% in unaffected 
controls (Verma et al., 2002). Lauenborg et al. (2005) estimated the risk of metabolic 
syndrome in a Danish cohort of women 9.8 years after delivery. Women with previous 
GDM had a 3-fold higher risk of metabolic syndrome compared to non-GDM controls 
(Lauenborg et al., 2005). A similar study in Europe reported prevalences of metabolic 
syndrome of 21% and 4.6%, respectively, 8.5 years’ postpartum (Bo et al., 2004b). Indeed, 
prior gestational hyperglycemia in the absence of fulfilling the overt criteria for GDM results 
in a future risk of metabolic syndrome 2-4 times that of those with normoglycemia in 
pregnancy. This risk is 10 times higher in women with concomitant pre-pregnancy obesity 
(Bo et al., 2004a). Thus, even mild gestational hyperglycemia predicts metabolic syndrome 
(Bo et al., 2004b), and metabolic syndrome is increasingly more likely to develop over time 
following the index pregnancy (Bo et al., 2006). These studies highlight the chronic nature of 
the metabolic dysfunction associated with GDM. Furthermore, they raise the possibility that 
a diagnosis of GDM may indicate the presence of an underlying latent metabolic syndrome 
(Retnakaran et al., 2010b). 
4.2 Development of metabolic syndrome in the early postpartum after GDM 
Recent evidence implicates GDM as an early expression of metabolic syndrome (Haffner & 
Taegtmeyer, 2003). Indeed, it was recently reported that both GDM (OR 2.05, 95% CI 1.07-
3.94) and the milder state of gestational impaired glucose tolerance (GIGT) (OR 2.16, 95% CI 
1.05-4.42) independently predict postpartum metabolic syndrome by 3 months postpartum, 
even after adjustment for covariates (Retnakaran et al., 2010d). Furthermore, by 3 months 
postpartum women with GDM and GIGT also exhibit non-traditional risk factors associated 
with metabolic syndrome, including low levels of adiponectin and increased serum CRP 
(Retnakaran et al., 2010c). While many of the metabolic disturbances of pregnancy resolve 
after delivery, growing evidence supports the concept that pregnancy provides an 
opportunity to observe a pronounced expression of an otherwise subclinical metabolic 
disorder. Such metabolic disturbances, which include the metabolic syndrome component 
disorders, may indeed be apparent prior to the diagnosis of GDM.  
5. Prediction of GDM by metabolic syndrome components and associated 
risk factors 
5.1 Prediction of GDM by metabolic syndrome components in early pregnancy  
It is quite likely that the metabolic syndrome exists prior to the development of GDM. 
Indeed, GDM has even been proposed to be a component of the metabolic syndrome (Clark 
et al. 1997). In their study, Clark et al. (1997) showed that, at the time of their antepartum 
OGTT, women with GDM expressed markers of the metabolic syndrome, including low 
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serum HDL cholesterol and higher fasting plasma insulin, triglycerides, free fatty acids and 
pre-pregnancy BMI. These common features of the metabolic syndrome were each 
individually predictive of GDM, and persisted after adjustment for differences in BMI 
(Clark et al., 1997).  
In addition to conventional measures of metabolic syndrome, several non-traditional 
biomarkers have also emerged as possible predictors of GDM. As discussed earlier, low 
adiponectin is a risk factor for T2DM and an emerging risk factor for metabolic syndrome 
and GDM. Using a prospective nested case-control study design, Williams et al. (2004) 
determined whether first trimester hypoadiponectinemia predicts GDM. They found that 
73% of those with GDM had a low adiponectin level compared to 33% of controls (adjusted 
OR 4.6, 95% CI 1.8-11.6) (Williams et al., 2004). Similarly, Lain and colleagues (2008) found 
that women with low adiponectin concentrations in the first trimester were much more 
likely to be diagnosed with GDM (OR 10.2, 95% CI 1.3, 78.7) (Lain et al., 2008).  
In choosing an optimal early serum marker to predict GDM, Smirnakis and colleagues 
(2007) compared SHBG, high-sensitive CRP, and the homeostasis model of assessment of 
insulin resistance (HOMA-IR) in late first trimester and early second trimester of pregnancy 
(Smirnakis et al., 2007). Serum SHBG was lower, and serum CRP higher, in women who 
went on to develop GDM, who also had  elevated HOMA-IR in the second trimester. After 
multivariate analysis, SHBG emerged as the best predictor of GDM (Smirnakis et al., 2007). 
Alternately, Wolf et al. (2003) found that the risk of developing GDM was higher in women 
in the upper vs. lower tertiles of first-trimester CRP, after adjusting for confounders (OR 3.6, 
95% CI 1.2-11.4). Importantly, the association was attenuated when BMI was included in the 
analysis (OR 1.5, 95% CI 0.4-5.5) (Wolf et al., 2003), suggesting that obesity confounds the 
relation between inflammation and GDM.  
Qiu and colleagues (2004) found that, even after adjusting for maternal pre-pregnancy BMI 
and other confounders, women with CRP in the highest vs. lowest tertiles experienced a 3.5-
times increased risk of GDM (95% CI 1.2-9.8) (Qiu et al., 2004). Moreover,  even lean women 
had an OR for GDM of 3.7 (95% CI 1.6-8.7), suggesting that the association between elevated 
CRP and GDM may not solely depend on the presence of maternal obesity (Qiu et al., 2004). 
However, Savvidou and colleagues (2010) evaluated various first-trimester conventional 
and novel biomarkers, including adiponectin and CRP, and found only a low HDL-C and a 
high tissue plasminogen activator were significant independent predictors of GDM 
(Savvidou et al., 2010). Laughon et al (2009) reported that a first trimester concentration of 
uric acid in the highest quartile had an OR for GDM of 3.25 (95% CI 1.35-7.83), after 
adjusting for BMI and age (Laughon et al., 2009). Together, these emerging risk factors 
present an opportunity for early detection of GDM, and possibly, the identification of an 
effective tool for long-term prevention of metabolic syndrome. 
It is likely that components of metabolic syndrome exist before and after GDM. Similar to 
T2DM, where persons with IGT and IFG are at significant risk of T2DM, so too may be the 
case for metabolic syndrome in early pregnancy. Ray and colleagues (2010) coined the term 
“gestational prediabetes” to describe the absence of diabetes before pregnancy, and the 
presence of a blood glucose level (or a related marker) in early pregnancy that is higher than 
normal, but not yet high enough to meet the diagnostic criteria for GDM (Ray et al., 2010). 
Given the promising findings of using emerging biomarkers to detect dysmetabolism in 
early pregnancy and predict GDM, the next step is to identify a robust biomarker that can be 
assayed at a low cost in early pregnancy. Since they are chronic in nature, metabolic 
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abnormalities likely precede pregnancy, which means that they should be detectable in early 
pregnancy as well. 
5.2 Prediction of GDM by metabolic syndrome components prior to pregnancy 
A modest body of literature exists about the existence of metabolic syndrome prior to the 
detection of GDM. Gunderson and colleagues (2009) examined pre-pregnancy 
cardiometabolic risk factors and the risk of GDM in subsequent pregnancies. They found 
that metabolic impairment often predated the onset of GDM, and that 27% of overweight 
women with one or more cardiometabolic risk factors developed GDM (Gunderson et al., 
2009). Normoglycemia with at least one metabolic risk factor (i.e., low plasma HDL-C and/or 
hyperinsulinemia) was present before pregnancy in 34% of those who developed GDM; 
among overweight women, the presence of any cardiometabolic feature was associated with 
an almost 4 times higher risk of GDM. Hedderson and Ferrara (2008) measured blood pressure 
before pregnancy and in early pregnancy, and found that women with mild hypertension in 
early pregnancy had a  small increased risk of GDM (OR 1.56, 95% CI 1.16-2.10). Those with 
frank hypertension had a 2-fold increased risk of GDM (OR 2.04, 95% CI 1.14-3.65) compared 
to normotensive women, even after adjusting for confounders. These findings were paralleled 
by mild (OR 1.44, 95 CI 0.95-2.19) and frank (OR 2.01, 95% CI 1.01-3.99) hypertension detected  
before pregnancy (Hedderson & Ferrara, 2008).  
6. Conclusions 
We have reviewed the parallels and associations between the metabolic syndrome and 
GDM. Both conditions have had multiple sets of diagnostic criteria and a history marked by 
controversies about their definition, clinical utility and significance. Both conditions identify 
a patient population that has an increased future risk of T2DM and CVD. Furthermore, both 
conditions have been associated with a similar set of emerging non-traditional risk factors. 
Consistent with these parallels, GDM predicts an increased risk of metabolic syndrome both 
in the early postpartum and in the years thereafter. Moreover, it is now becoming apparent 
that the metabolic syndrome and its associated risk factors may precede the diagnosis of 
GDM, both in early gestation and prior to the pregnancy. Taken together, these data suggest 
that GDM may represent a transient ‘unmasking’ of a latent metabolic syndrome, which 
may extend in both directions through (i) the pre-gravid state and early pregnancy, and (ii) 
the early and late postpartum. Figure 3 illustrates this lifetime continuum that may link 
metabolic syndrome, GDM, T2DM, and CVD. The chronic nature of the features of 
metabolic syndrome suggests that what we know about the temporal relation between 
metabolic syndrome, GDM, T2DM, and CVD is limited. The global burden of diabetes has 
been estimated at more than 171 million individuals with an expected increase to 366 
million by 2030 (Wild et al., 2004). The prevalence of obesity and related metabolic 
dysfunction worldwide is a vivid demonstration of the undiscriminating potential of cardio-
metabolic diseases across ethnicities and age groups. In this context, the emerging relation 
between metabolic syndrome and GDM may offer the opportunity for early detection of at-
risk individuals, long before the manifestation of overt disease. Ideally, this opportunity 
may lead to new strategies for early risk modification and ultimately disease prevention. As 
such, the emerging relation between metabolic syndrome and GDM represents an important 
area of research that may hold both clinical and public health implications. 
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Fig. 3. Theoretical framework and conceptual model for latent metabolic syndrome 
preceding GDM. 
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